RxDoctor Payments Data

Jonathan Picard, MD

Urology · Mount Pleasant, SCNPI 1619142841

Payments from drug & device makers

$6,373in general payments, 2019–2025

Across 196 payments — averaging $32.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$2K
  • Dendreon Pharmaceuticals LLC$601
  • Boston Scientific$311
  • Sumitomo Pharma America, Inc.$293
  • Merck$284
  • Pfizer$270
  • plus $3K from 33 others

What the payments were for

  • Travel & lodging$92515%
  • Food & beverage$5,34884%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,373 in reported general payments places this provider in the 65th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$444,789
Medicare patients
902
Services billed
9,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix200$530,766
MyrbetriqMirabegron64$63,378
GemtesaVibegron46$34,062
Mirabegron ErMirabegron18$13,747
Testosterone20$7,098
Tamsulosin Hcl473$6,491
Silodosin48$3,656
Finasteride179$3,147
Solifenacin Succinate48$2,790
Oxybutynin Chloride ErOxybutynin Chloride67$1,571
Dutasteride42$1,526
Alfuzosin Hcl ErAlfuzosin Hcl65$1,250
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav39$769
Tadalafil21$683
Testosterone Cypionate13$511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$293$564,828246 claims
Astellas Pharma US IncMyrbetriq$247$63,37864 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 196 urology providers in South Carolina.

Other urology in Mount Pleasant

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →